ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) is excited to announce its participation in the 26th Annual HC Wainwright Global Investment Conference. The conference, held in-person at the Lotte New York Palace Hotel in Midtown Manhattan and virtually from September 9-11, 2024, offers a platform for networking, one-on-one meetings, and company presentations.
IPA’s management team invites shareholders and interested parties to attend. Admission is complimentary for eligible investors. The Company will host one-on-one meetings, and those interested in scheduling an appointment can contact Jennifer K. Zimmons, PhD, MBA at Quantum Media via email at [email protected] or phone at +1.917.214.3514.
The Global Investment Conference brings together professionals and investors from various sectors, including biotechnology and life sciences, providing opportunities for networking and in-depth discussions.
For more information or to register for the conference, please visit: HCW Events.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotherapeutics research and technology group that utilizes systems biology, multi-omics modeling, and advanced artificial intelligence to enhance its proprietary technologies in antibody discovery. The IPA Family, including subsidiaries Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) BV, specializes in the discovery, development, and licensing of therapeutic biologics to support its partners in developing novel biologics against challenging targets.
